A Lawrie
Overview
Explore the profile of A Lawrie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McMillan A, Phillips E, Kirkwood A, Barrans S, Burton C, Rule S, et al.
Ann Oncol
. 2020 May;
31(9):1251-1259.
PMID: 32464282
Background: Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates....
2.
Bellantuono I, de Cabo R, Ehninger D, Di Germanio C, Lawrie A, Miller J, et al.
Nat Protoc
. 2020 Jan;
15(2):540-574.
PMID: 31915391
The number of people aged over 65 is expected to double in the next 30 years. For many, living longer will mean spending more years with the burdens of chronic...
3.
Gleeson M, Counsell N, Cunningham D, Chadwick N, Lawrie A, Hawkes E, et al.
Ann Oncol
. 2017 Sep;
28(10):2511-2516.
PMID: 28961838
Background: Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis of CNS relapse for patients treated within...
4.
Kuhnl A, Cunningham D, Counsell N, Hawkes E, Qian W, Smith P, et al.
Ann Oncol
. 2017 Apr;
28(7):1540-1546.
PMID: 28398499
Background: There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI...
5.
Thompson A, Dickinson R, Murphy F, Thomson J, Marriott H, Tavares A, et al.
Sci Immunol
. 2017 Apr;
2(8).
PMID: 28386604
Hypoxia and bacterial infection frequently co-exist, in both acute and chronic clinical settings, and typically result in adverse clinical outcomes. To ameliorate this morbidity, we investigated the interaction between hypoxia...
6.
Perez de Ciriza C, Lawrie A, Varo N
Int J Endocrinol
. 2015 Jun;
2015:564934.
PMID: 26078757
Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD,...
7.
Cookson P, Lawrie A, Green L, Dent E, Proffitt S, Bashir S, et al.
Vox Sang
. 2014 Dec;
108(2):160-8.
PMID: 25469449
Background: We assessed the haemostatic capacity of thawed plasma produced after ambient storage of whole blood for 24 h (RTFP24), and the supernatant of buffy-coat derived platelet concentrates (PC). Methods:...
8.
Lawrie A
Pulm Circ
. 2014 Jul;
4(1):2-9.
PMID: 25006416
The failure to translate positive results from preclinical studies into new clinical therapies is a major problem throughout medical research. Specifically, in pulmonary hypertension, numerous research studies have shown beneficial...
9.
Perez de Ciriza C, Lawrie A, Varo N
Clin Biochem
. 2014 May;
47(13-14):1279-85.
PMID: 24845712
Introduction: Osteoprotegerin (OPG), an osteoclastogenesis inhibitor implicated in bone remodelling, has emerged as a potential biomarker for cardiovascular disease. In order to implement OPG determination in the clinical laboratory, it...
10.
Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M
Int J Lab Hematol
. 2012 Sep;
35(1):1-13.
PMID: 22978493
No abstract available.